JP Patent

JP7393485B2 — 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用

Assigned to ドイチェス クレブスフォルシュンクスツェントルム · Expires 2023-12-06 · 2y expired

What this patent protects

Patent listed against lutetium-lu-177-vipivotide-tetraxetan.

Drugs covered by this patent

Patent Metadata

Patent number
JP7393485B2
Jurisdiction
JP
Classification
—
Expires
2023-12-06
Drug substance claim
No
Drug product claim
No
Assignee
ドイチェス クレブスフォルシュンクスツェントルム
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.